Recent M&A activity at the JP Morgan Healthcare Conference features J&J, Eli Lilly, and GSK making significant acquisitions.
Chicago: So, the JP Morgan Healthcare Conference is buzzing this year! J&J, Eli Lilly, and GSK are making some big moves. J&J is set to acquire Intra-Cellular Therapies for about $14.6 billion. That’s a hefty price, but it’s a smart play to boost their neuroscience lineup.
Lilly isn’t sitting back either. They’re picking up a promising breast cancer treatment from Scorpion Therapeutics for around $2.5 billion. It’s a cool strategy to strengthen their oncology pipeline.
GSK is also in the game, planning to buy IDRx, a biotech focused on gastrointestinal cancers. They’re putting down $1 billion upfront, plus some extra for regulatory milestones.
With all this action, it looks like 2025 might see a surge in healthcare M&A deals. After a quiet 2024, these announcements could signal a comeback. Everyone’s looking to fill their R&D pipelines, especially with some blockbuster drugs losing exclusivity soon.
So, keep an eye on these companies! They’re making moves that could shake things up in the healthcare sector.
